BEIGENE (06160) announced that on April 24, 2026, its wholly-owned subsidiary, BEIGENE Guangzhou, entered into a collaboration agreement with Huahui Anjian. Under the agreement, Huahui Anjian granted BEIGENE Guangzhou an exclusive option to obtain a worldwide, exclusive license for the development, production, and commercialization of Huahui Anjian's investigational trispecific compound targeting PD-1, CTLA-4, and VEGF-A—including HH160—and any products containing such compounds, for all indications.

Pursuant to the agreement, BEIGENE Guangzhou will pay Huahui Anjian an upfront fee of $20 million. If BEIGENE Guangzhou exercises the option within a specified period, Huahui Anjian will be eligible to receive an additional option exercise payment of $100 million. Upon achieving development and regulatory milestones, Huahui Anjian may receive up to $374 million in payments. Following the attainment of sales milestones, Huahui Anjian could receive up to $1.53 billion. Additionally, Huahui Anjian is entitled to receive tiered royalties.

Furthermore, Huahui Anjian has agreed to compensate BEIGENE Guangzhou for the licensing of related intellectual property to Huahui Anjian—limited to the extent necessary for Huahui Anjian to fulfill its obligations under the agreement—once relevant milestones are achieved.